Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.
Details
Serval ID
serval:BIB_8C325269EDBB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.
Journal
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
ISSN
2212-4411 (Electronic)
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
116
Number
3
Pages
313-320
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
PURPOSE: To assess the clinical profile and prognostic factors in patients with adenosquamous carcinoma (ASC) of the head and neck treated by surgery and/or radiation therapy with or without chemotherapy.
METHODS: Data from 20 patients with stage I-II (n = 4), III (n = 5), or IVA (n = 11) head and neck ASC, treated between 1989 and 2010 were collected in a retrospective multicenter Rare Cancer Network study. Surgery was performed in 16 patients. Seventeen patients received combined modality treatment.
RESULTS: After a median follow-up of 15.5Â months, 12 patients recurred. The 3-year and median overall survival, disease-free survival (DFS), and loco-regional control were 52% and 39Â months, 32% and 12Â months, and 47% and 33Â months respectively. In multivariate analysis, DFS was negatively influenced by the presence of extracapsular extension and advanced stage.
CONCLUSION: Overall prognosis of locoregionally advanced ASC remains poor. However, early stage ASC patients managed with combined modality treatment may have prolonged DFS.
METHODS: Data from 20 patients with stage I-II (n = 4), III (n = 5), or IVA (n = 11) head and neck ASC, treated between 1989 and 2010 were collected in a retrospective multicenter Rare Cancer Network study. Surgery was performed in 16 patients. Seventeen patients received combined modality treatment.
RESULTS: After a median follow-up of 15.5Â months, 12 patients recurred. The 3-year and median overall survival, disease-free survival (DFS), and loco-regional control were 52% and 39Â months, 32% and 12Â months, and 47% and 33Â months respectively. In multivariate analysis, DFS was negatively influenced by the presence of extracapsular extension and advanced stage.
CONCLUSION: Overall prognosis of locoregionally advanced ASC remains poor. However, early stage ASC patients managed with combined modality treatment may have prolonged DFS.
Pubmed
Web of science
Create date
12/09/2013 18:23
Last modification date
20/08/2019 15:50
Usage data
